Clinical implication of p53 overexpression in breast cancer patients younger than 50 years with a triple-negative subtype who undergo a modified radical mastectomy

Japanese Journal of Clinical Oncology

Volumn 41, Issue 7, 2011, Pages 854-866

  Lee, Dong Soo ^a   Kim, Sung Hwan ^a   Suh, Young Jin ^a   Kim, Suzy ^a   Kim, Hoon Kyo ^a   Shim, Byoung Yong ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Breast neoplasms; Genes; Mastectomy; Modified radical; Tumor suppressor; Tumor suppressor protein p53

Indexed keywords

ANASTROZOLE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; HORMONE RECEPTOR; LETROZOLE; METHOTREXATE; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN; TOREMIFENE;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INVASION; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; DISTANT METASTASIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL RECORD REVIEW; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MASTECTOMY, MODIFIED RADICAL; MEDICAL RECORDS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 79960041858     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr066     Document Type: Article

References (32)

1. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894-904.
2. Ebeling FG, Stieber P, Untch M, Nagel D, Konecny GE, Schmitt UM, et al. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. r J Cancer 2002;86:1217-22.
3. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 002;347:1566-75.
4. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002;94:116-28.
5. Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009;116:53-68.
6. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
7. Nagasaki K, Miki Y. Gene expression profiling of breast cancer. Breast Cancer 2006;13:2-7.
8. Ross JS. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome. Adv Anat Pathol 2009;16:204-15.
9. Györffy B, Schäfer R. Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients. Breast Cancer Res reat 2009;118:433-41.
10. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005;24:2899-908.
11. Patocs A, Zhang L, Xu Y, Weber F, Caldes T, Mutter GL, et al. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 007;357:2543-51.
12. MacGrogan G, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, et al. Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases. Breast Cancer Res Treat 1995;36:71-81.
13. Montero S, Guzmán C, Vargas C, Ballestín C, Cortés-Funes H, Colomer R. Prognostic value of cytosolic p53 protein in breast cancer. Tumour Biol 001;22:337-44.
14. Querzoli P, Albonico G, di Iasio MG, Ferretti S, Rinaldi R, Cariello A, et al. Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in oung women. Breast Cancer Res Treat 2001;66:135-42.
15. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-312.
16. Bull SB, Ozcelik H, Pinnaduwage D, Blackstein ME, Sutherland DA, Pritchard KI, et al. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. J Clin Oncol 2004;22:86-96.
17. Talley L, Chhieng DC, Bell WC, Grizzle WE, Frost AR. Immunohistochemical detection of EGFR, p185(erbB-2), Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women. Biotech Histochem 2008;83:5-14.
18. Chae BJ, Bae JS, Lee A, Park WC, Seo YJ, Song BJ, et al. p53 as a specific prognostic factor in triple-negative breast cancer. Jpn J Clin Oncol 009;39:217-24.
19. Kim HS, Yom CK, Kim HJ, Lee JW, Sohn JH, Kim JH, et al. Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy. Breast Cancer Res Treat 2010;121:777-88.
20. Pharoah PD, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 1999;80:1968-73.
21. Valgardsdottir R, Tryggvadottir L, Steinarsdottir M, Olafsdottir K, Jonasdottir S, Jonasson JG, et al. Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis. APMIS 1997;105:121-30.
22. Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res 2003;1:1001-8.
23. Boersma BJ, Howe TM, Goodman JE, Yfantis HG, Lee DH, Chanock SJ, et al. Association of breast cancer outcome with status of p53 and MDM2 NP309. J Natl Cancer Inst 2006;98:911-9.
24. Logullo AF, de Moura RP, Nonogaki S, Kowalski LP, Nagai MA, Simpson AJ. A proposal for the integration of immunohistochemical staining and DNA-based techniques for the determination of TP53 mutations in human carcinomas. Diagn Mol Pathol 2000;9:35-40.
25. Seshadri R, Leong AS, McCaul K, Firgaira FA, Setlur V, Horsfall DJ. Relationship between p53 gene abnormalities and other tumour characteristics in reast-cancer prognosis. Int J Cancer 1996;69:135-41.
26. Falette N, Paperin MP, Treilleux I, Gratadour AC, Peloux N, Mignotte H, et al. Prognostic value of P53 gene mutations in a large series of node-egative breast cancer patients. Cancer Res 1998;58:1451-5.
27. Andersson J, Larsson L, Klaar S, Holmberg L, Nilsson J, Inganäs M, et al. Worse survival for TP53 (p53)-mutated breast cancer patients receiving djuvant CMF. Ann Oncol 2005;16:743-8.
28. Yamashita H, Toyama T, Nishio M, Ando Y, Hamaguchi M, Zhang Z, et al. p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res 2006;8:R48.
29. Bertheau P, Espié M, Turpin E, Lehmann J, Plassa LF, Varna M, et al. TP53 status and response to chemotherapy in breast cancer. Pathobiology 008;75:132-9.
30. Liang Y, Besch-Williford C, Hyder SM. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein. Int J Oncol 2009;35:1015-23.
31. Liang Y, Besch-Williford C, Benakanakere I, Thorpe PE, Hyder SM. Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors. Breast Cancer Res Treat 2011;125:407-20.
32. Zhang GJ, Tsuda H, Adachi I, Fukutomi T, Yamamoto H, Hirohashi S. Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins. Jpn J Clin Oncol 1997;27:371-7.